【摘要】 [目的]探讨荧光原位杂交(FISH)与免疫组织化学方法(IHC)检测乳腺癌组织中人类表皮生长因子受体2(Her-2)表达结果的差异。[方法]采用FISH和IHC法分别检测508例乳腺癌标本中Her-2基因扩增和Her-2蛋白表达状况。[结果]在IHC法检测Her-2蛋白表达0/+的104例(20.47%)标本中,FISH检出13例(2.56%)Her-2基因扩增,89例(17.52%)为非扩增,2例(0.39%)为可疑;Her-2蛋白表达++的245例(48.23%)标本中,FISH检出121例(23.82%)Her-2基因扩增,120例(23.62%)为非扩增,4例(0.79%)为可疑;IHC在Her-2蛋白表达+++的159例(31.30%)标本中,FISH检出137例(26.97%)Her-2基因扩增,22例(4.33%)为非扩增。[结论]对于IHC法初筛Her-2蛋白为++～+++的患者必须进行FISH检测,以明确Her-2基因的状态,从而指导临床医师诊断治疗。更多还原

【Abstract】 [Purpose] To investigate the difference of Her-2 expression detected by fluorescence in situ hybridization(FISH) and by immunohistochemistry(IHC) in breast cancer.[Methods] Both IHC and FISH techniques were performed to detect Her-2 gene amplification and Her-2 protein expression respectively in 508 samples with breast cancer.[Results] Among 104 cases(20.47%) with 0/+ Her-2 protein expression detected by IHC,13 cases(2.56%) were Her-2 gene amplification detected by FISH;89 cases(17.52%),non-amplification;2 cases(0.39%),suspicious.Among 245 cases(48.23%) with ++ Her-2 protein expression,121 cases(23.82%) were Her-2 gene amplification;120 cases(23.62%),non-amplification;4 cases(0.79%),suspicious.Among 159 cases(31.30%) with +++ Her-2 protein expression,137 cases(2.97%) were Her-2 gene amplification;22 cases(4.33%),non-amplification.[Conclusion] Detecting the amplification of Her-2 gene with FISH may be helpful to know Her-2 gene status for treatment decision in breast cancer patients with positive Her-2 expression ++～+++ by IHC.更多还原